Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

USA - NASDAQ:RVPH - US76152G1004 - Common Stock

0.5577 USD
0 (-0.55%)
Last: 11/12/2025, 2:23:57 PM
Fundamental Rating

0

RVPH gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RVPH have multiple concerns. RVPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RVPH has reported negative net income.
In the past year RVPH has reported a negative cash flow from operations.
In the past 5 years RVPH reported 4 times negative net income.
RVPH had a negative operating cash flow in each of the past 5 years.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RVPH has a Return On Assets of -233.02%. This is amonst the worse of the industry: RVPH underperforms 90.05% of its industry peers.
Industry RankSector Rank
ROA -233.02%
ROE N/A
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RVPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for RVPH has been increased compared to 1 year ago.
The number of shares outstanding for RVPH has been increased compared to 5 years ago.
RVPH has a worse debt/assets ratio than last year.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RVPH has an Altman-Z score of -26.48. This is a bad value and indicates that RVPH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.48, RVPH is doing worse than 85.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.48
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.90 indicates that RVPH may have some problems paying its short term obligations.
The Current ratio of RVPH (0.90) is worse than 84.82% of its industry peers.
A Quick Ratio of 0.90 indicates that RVPH may have some problems paying its short term obligations.
RVPH's Quick ratio of 0.90 is on the low side compared to the rest of the industry. RVPH is outperformed by 77.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RVPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.2%
EPS Next 2Y26.86%
EPS Next 3Y18.09%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as RVPH's earnings are expected to grow with 18.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.86%
EPS Next 3Y18.09%

More info and screens

0

5. Dividend

5.1 Amount

RVPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (11/12/2025, 2:23:57 PM)

0.5577

0 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-17 2025-11-17
Inst Owners21.06%
Inst Owner Change0.26%
Ins Owners5.17%
Ins Owner Change0%
Market Cap53.73M
Revenue(TTM)N/A
Net Income(TTM)-27.11M
Analysts81.54
Price Target4.37 (683.58%)
Short Float %24.37%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.61%
Min EPS beat(2)-6.95%
Max EPS beat(2)30.16%
EPS beat(4)3
Avg EPS beat(4)13.79%
Min EPS beat(4)-6.95%
Max EPS beat(4)31.6%
EPS beat(8)6
Avg EPS beat(8)10.88%
EPS beat(12)8
Avg EPS beat(12)-2.48%
EPS beat(16)11
Avg EPS beat(16)0.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.53%
PT rev (3m)-54.55%
EPS NQ rev (1m)4.76%
EPS NQ rev (3m)22.29%
EPS NY rev (1m)2.99%
EPS NY rev (3m)12.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -233.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z -26.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y50.2%
EPS Next 2Y26.86%
EPS Next 3Y18.09%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.89%
OCF growth 3YN/A
OCF growth 5YN/A

REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ

Can you provide the ChartMill fundamental rating for REVIVA PHARMACEUTICALS HOLDI?

ChartMill assigns a fundamental rating of 0 / 10 to RVPH.


Can you provide the valuation status for REVIVA PHARMACEUTICALS HOLDI?

ChartMill assigns a valuation rating of 0 / 10 to REVIVA PHARMACEUTICALS HOLDI (RVPH). This can be considered as Overvalued.


How profitable is REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a profitability rating of 0 / 10.